Gilead Sciences Inc logo

GILD - Gilead Sciences Inc Share Price

$68.16 1.2  1.8%

Last Trade - 25/01/21

Large Cap
Market Cap £62.48bn
Enterprise Value £66.39bn
Revenue £16.93bn
Position in Universe 140th / 6629
Unlock GILD Revenue
Relative Strength (%)
1m +16.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
24,890 32,639 30,390 26,107 22,127 22,449 24,147 24,198 -2.0%
+301.7 +60.7 -12.4 -24.9 -45.5 +0.9 +58.9 -0.57
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, GileadSciences, Inc. revenues increased 4% to $17.27B. Net losstotaled $1.43B vs. income of $2.69B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net loss reflects Otherincome (expense), net - Bal decrease from $476M (income) to$1.75B (expense), Selling, general and administrative expeincrease of 8% to $3.42B (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GILD
Graphical History


GILD Revenue Unlock GILD Revenue

Net Income

GILD Net Income Unlock GILD Revenue

Normalised EPS

GILD Normalised EPS Unlock GILD Revenue

PE Ratio Range

GILD PE Ratio Range Unlock GILD Revenue

Dividend Yield Range

GILD Dividend Yield Range Unlock GILD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GILD EPS Forecasts Unlock GILD Revenue
Profile Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 22, 1987
Public Since January 1, 1992
No. of Shareholders: 473
No. of Employees: 11,800
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Global 100, Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 1,253,528,149
Free Float (0.0%)
Eligible for
GILD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GILD
Upcoming Events for GILD
Tuesday 2nd February, 2021 Estimate
Q4 2020 Gilead Sciences Inc Earnings Release
Wednesday 28th April, 2021 Estimate
Q1 2021 Gilead Sciences Inc Earnings Release
Frequently Asked Questions for Gilead Sciences Inc
What is the Gilead Sciences Inc share price?

As of 25/01/21, shares in Gilead Sciences Inc are trading at $68.16, giving the company a market capitalisation of £62.48bn. This share price information is delayed by 15 minutes.

How has the Gilead Sciences Inc share price performed this year?

Shares in Gilead Sciences Inc are currently trading at $68.16 and the price has moved by 7.93% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Gilead Sciences Inc price has moved by -8.86% over the past year.

What are the analyst and broker recommendations for Gilead Sciences Inc?

Of the analysts with advisory recommendations for Gilead Sciences Inc, there are there are currently 6 "buy" , 16 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Gilead Sciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Gilead Sciences Inc next release its financial results?

Gilead Sciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Gilead Sciences Inc dividend yield?

The Gilead Sciences Inc dividend yield is 3.92% based on the trailing twelve month period.

Does Gilead Sciences Inc pay a dividend?

Last year, Gilead Sciences Inc paid a total dividend of 2.67, and it currently has a trailing dividend yield of 3.92%. Looking ahead, Gilead Sciences Inc has not announced an ex-dividend date yet.

When does Gilead Sciences Inc next pay dividends?

Gilead Sciences Inc has yet to annouce their ex-dividend date. The historic dividend yield on Gilead Sciences Inc shares is currently 3.92%.

How do I buy Gilead Sciences Inc shares?

To buy shares in Gilead Sciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Gilead Sciences Inc?

Shares in Gilead Sciences Inc are currently trading at $68.16, giving the company a market capitalisation of £62.48bn.

Where are Gilead Sciences Inc shares listed? Where are Gilead Sciences Inc shares listed?

Here are the trading details for Gilead Sciences Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: GILD
What kind of share is Gilead Sciences Inc?

Based on an overall assessment of its quality, value and momentum, Gilead Sciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Gilead Sciences Inc share price forecast 2021?

Shares in Gilead Sciences Inc are currently priced at $68.16. At that level they are trading at 6.88% discount to the analyst consensus target price of 0.00.

Analysts covering Gilead Sciences Inc currently have a consensus Earnings Per Share (EPS) forecast of 6.842 for the next financial year.

How can I tell whether the Gilead Sciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gilead Sciences Inc. Over the past six months, the relative strength of its shares against the market has been -21.11%. At the current price of $68.16, shares in Gilead Sciences Inc are trading at 0.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Gilead Sciences Inc PE Ratio?

The Gilead Sciences Inc PE ratio based on its reported earnings over the past 12 months is 70.83. The shares are currently trading at $68.16.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Gilead Sciences Inc?

Gilead Sciences Inc's management team is headed by:

Kevin Lofton - LED
Jacqueline Barton - IND
Andrew Dickinson - CFO
Daniel O'Day - CHM
Brett Pletcher - EVP
Johanna Mercier - OTH
Jyoti Mehra - EVP
Merdad Parsey - OTH
Michael Quigley - SVP
Linda Higgins - SVP
Javier Rodriguez - DRC
Anthony Welters - DRC
Jeffrey Bluestone - DRC
Who are the major shareholders of Gilead Sciences Inc?

Here are the top five shareholders of Gilead Sciences Inc based on the size of their shareholding:

Capital Research Global Investors Investment Advisor
Percentage owned: 9.34% (117.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.19% (102.7m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.49% (81.4m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.55% (57.0m shares)
Capital International Investors Investment Advisor
Percentage owned: 3.87% (48.5m shares)
Similar to GILD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.